Pharma BD Deal Intelligence
Vertex and CRISPR Therapeutics entered a strategic collaboration to use CRISPR/Cas9 gene editing for hemoglobinopathies (sickle cell disease and beta-thalassemia). This led to the development and 2023 FDA approval of Casgevy (exagamglogene autotemcel), the first CRISPR-based gene therapy approved in the US.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated / CRISPR Therapeutics AG (this deal) | 2015 | $2.6B | 85 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Vertex Pharmaceuticals Incorporated / Semma Therapeutics Inc. | 2019 | $950M | 86 |
| Vertex Pharmaceuticals Incorporated / Concert Pharmaceuticals, Inc. | 2017 | $250M | 85 |
| Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences | 2024 | $4.9B | 78 |
| Vertex Pharmaceuticals Incorporated / Crinetics Pharmaceuticals, Inc. | 2026 | $10.0B | 68 |
| Vertex Pharmaceuticals Incorporated / ViaCyte Inc. | 2022 | $320M | 60 |
← Browse all deals · How we score deals
More: 2015 deals · Vertex Pharmaceuticals Incorporated deals · Gene Therapy deals